BRIGHT: 5-Yr Follow-up of First-line BR vs R-CHOP/R-CVP in Pts With iNHL or MCL

Source: 2017 American Society of Clinical Oncology Annual Meeting*
Download Slideset
June 2-6, 2017; Chicago, Illinois
BR associated with significantly increased 5-year PFS, duration of response, and event-free survival vs R-CHOP/R-CVP in overall patient population, particularly in MCL subgroup.
Format: Microsoft PowerPoint (.ppt)
File Size: 714 KB
Released: June 5, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings